Luigi Grasso
Gründer bei Navrogen, Inc.
Profil
Luigi Grasso was the founder of two companies, Morphotek, Inc. (founded in 2000) and Navrogen, Inc. (founded in 2017), where he held the title of Chief Scientific Officer and Director, Chief Scientific Officer & Senior VP respectively.
He worked at Morphotek, Inc. from 2011 to 2018.
Dr. Grasso holds a doctorate degree from the University of Catania.
Aktive Positionen von Luigi Grasso
| Unternehmen | Position | Beginn |
|---|---|---|
Navrogen, Inc.
 Navrogen, Inc. Pharmaceuticals: MajorHealth Technology Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA. | Gründer | 01.01.2017 |
Ehemalige bekannte Positionen von Luigi Grasso
| Unternehmen | Position | Ende |
|---|---|---|
Morphotek, Inc.
 Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Gründer | 01.04.2018 |
Ausbildung von Luigi Grasso
| University of Catania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Commercial Services |
Navrogen, Inc.
Navrogen, Inc. Pharmaceuticals: MajorHealth Technology Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
